BASI Bioanalytical Systems

Bioanalytical Systems to Release First Quarter Fiscal 2019 Results on Thursday, February 14, 2019

Bioanalytical Systems to Release First Quarter Fiscal 2019 Results on Thursday, February 14, 2019

WEST LAFAYETTE, Ind., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:) (“BASi” or the “Company”) today announced today that it will report financial results for the first quarter of fiscal 2019 ended December 31, 2018, prior to the market opening on Thursday, February 14, 2019. If there are any questions after the press release is issued, please direct your comments to the investor relations contact noted in this release.

About Bioanalytical Systems, Inc.

BASi is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations. The Company focuses on developing innovative services supporting its clients’ discovery and development objectives for improved decision-making and accelerated goal attainment. BASi products focus on increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Visit  for more information about BASi.

This release may contain forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to changes in the market and demand for our products and services, the development, marketing and sales of products and services, changes in technology, industry and regulatory standards, and various market and operating risks detailed in the company's filings with the U.S. Securities and Exchange Commission.

Company Contact:

Jill C. Blumhoff

Chief Financial Officer

Phone: 756.497.8381



EN
12/02/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bioanalytical Systems

MarketLine Department
  • MarketLine Department

Catalent Inc - Company Profile and SWOT Analysis

Summary Catalent Inc - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Catalent Inc (Catalent) provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The company offers complex advanced formulation delivery technol...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: March 20, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv,...

Bioanalytical Systems, Inc. Announces Corporate Name Change to Inotiv, Inc. WEST LAFAYETTE, Ind., March 19, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), a leading provider of nonclinical and analytical contract research services, today announced a change of the Company’s corporate name from Bioanalytical Systems, Inc. to Inotiv, Inc. The name change was approved by the Company’s shareholders on March 18, 2021, at the Company’s annual meeting of shareholders and became effective as of the filing of articles of amendment to th...

 PRESS RELEASE

Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan ...

Bioanalytical Systems, Inc., doing business as Inotiv, Announces Plan to Expand Service Offerings to Include Cardiovascular Safety Pharmacology WEST LAFAYETTE, Ind., March 17, 2021 (GLOBE NEWSWIRE) -- Bioanalytical Systems, Inc. (NASDAQ:BASI) (the “Company”, “We”, “Our” or “Inotiv”), doing business as Inotiv, a leading provider of nonclinical and analytical contract research services, today announced plans to expand the Company’s service offerings to add cardiovascular safety pharmacology capabilities to the existing capabilities for respiratory and central nervous system safety pharmacol...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Tables: March 13, 2021

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch